↓ Skip to main content

Dove Medical Press

Article Metrics

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia

Overview of attention for article published in Therapeutics and Clinical Risk Management, June 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

policy
1 policy source
twitter
6 tweeters

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
47 Mendeley
Title
A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
Published in
Therapeutics and Clinical Risk Management, June 2015
DOI 10.2147/tcrm.s73559
Pubmed ID
Authors

Simon Rule, David Tucker

Abstract

Although chemo-immunotherapy remains at the forefront of first-line treatment for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), small molecules, such as ibrutinib, are beginning to play a significant role, particularly in patients with multiply relapsed or chemotherapy-refractory disease and where toxicity is an overriding concern. Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase, which functions by irreversible inhibition of the downstream signaling pathway of the B-cell receptor, which normally promotes cell survival and proliferation. Early clinical trials have demonstrated excellent tolerability and a modest side-effect profile even in elderly and multiply pretreated patient cohorts. Although the majority of disease responses tend to be partial, efficacy data have also been encouraging with more than two-thirds of patients with CLL and MCL demonstrating a durable response, even in the high-risk disease setting. Resistance mechanisms are only partially understood and appear to be multifactorial, including the binding site mutation C481S, and escape through other common cell-signaling pathways. This article appraises the currently available data on safety and efficacy from clinical trials of ibrutinib in the management of MCL and CLL, both as a single agent and in combination with other therapies, and considers how this drug is likely to be used in future clinical practice.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 47 100%

Demographic breakdown

Readers by professional status Count As %
Other 11 23%
Student > Bachelor 8 17%
Researcher 7 15%
Student > Ph. D. Student 6 13%
Student > Master 5 11%
Other 3 6%
Unknown 7 15%
Readers by discipline Count As %
Medicine and Dentistry 20 43%
Agricultural and Biological Sciences 6 13%
Pharmacology, Toxicology and Pharmaceutical Science 5 11%
Biochemistry, Genetics and Molecular Biology 4 9%
Computer Science 1 2%
Other 5 11%
Unknown 6 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 August 2016.
All research outputs
#3,487,153
of 17,356,510 outputs
Outputs from Therapeutics and Clinical Risk Management
#161
of 1,100 outputs
Outputs of similar age
#51,767
of 238,471 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#9
of 50 outputs
Altmetric has tracked 17,356,510 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,100 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 238,471 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.